Poster Abstracts • OFID 2018:5 (Suppl 1) • S609 negatives. " We fit a statistical decision tree taking as inputs serial serology measurements and outputting a predicted disease category. Funded in part by the NCI Contract No. HHSN261200800001E. Funded in part by the Mexican Ministry of Health.
Background. Cytomegalovirus (CMV) infection is a common opportunistic infection associated with significant morbidity, mortality, and risk of allograft loss. Early detection of viremia and initiation of treatment prior to disease progression is paramount. Alternatively, in the absence of treatment, many patients also control CMV infection, including low-level viremia, without progressing to disease. Thus, many treatment decisions (e.g., viremia thresholds to initiate treatment) are not currently well-defined. Given the excessive toxicities and costs of antiviral therapy, there is growing interest in assays that measure CMV-specific T-cell immunity (TCI), which may predict protection against infection. The Viracor® CMV T-cell Immunity Panel (CMV-TCIP) uses flow cytometry and intracellular cytokine staining (ICS) to measure % of CMV-specific CD4+ and CD8+ T-cells. Other currently available TCI commercial assays measure only aggregate (CD4+ and CD8+) or CD8+ immune responses only.
Methods. We included patients who had CMV-TCIP results at Rhode Island Hospital (January 2016-February 2018) and who subsequently had at least one additional assessment for CMV viremia. CMV events were defined as rising viremia prompting initiation of treatment and were captured after the most recent CMV-TCIP result. We built CMV-protection relative-operating curves (ROC) for % of CD4+ and CD8+ CMV-specific T-cells.
Results. We analyzed 17 samples from 13 patients: 10 were SOT (eight kidney, two heart) recipients (seven CMV R+, three D+/R−); two had hematologic malignancies; one other was immunosuppressed (prednisone, infliximab) for autoimmune colitis. Four additional samples were excluded because of CD4+ or CD8+ ICS background positivity. The CMV-protection ROC AUC was significant for % of CMV-specific CD4+ but not CD8+ T-cells (Figure 1) . At a cut-off of 0.26% CMV-specific CD4+ T-cells, PPV was 90% (95% CI 71-100%), and NPV was 86% (95% CI 60-100%). In 14 of 17 cases (82%), the CMV-TCIP result was useful in guiding management.
Conclusion. In this small, single-center, heterogeneous series, the % of CMVspecific CD4+ T-cells measured by ICS was predictive of protection against CMV. The CMV-TCIP can be a useful, cost-effective test, and merits further validation in larger prospective studies. Background. Dengue is a re-emerging public health problem threatening the tropical developing world, mandating rapid diagnosis and supportive management in the absence of licensed vaccines or anti-dengue therapy. Regions endemic for dengue and related viruses are overwhelmed by the sudden surge of cases during outbreaks. It is difficult to justify confirmatory diagnosis of every case using WHO criteria or differentiate it from other concurrent viral illnesses. The study evaluated a rapid, sensitive and specific diagnostic methodology suitable for dengue outbreaks in resource limited facilities.
Rapid Diagnosis and Differentiation of Dengue During Peri-monsoon Season in Tropical Resource Limited Facilities
Methods. One hundred dengue patients as per WHO Criteria as well as 100 healthy controls from New Delhi, India were included. Samples collected on fifth day on onset of fever were tested by lateral flow immunochromatography (LF-ICT), IgM ELISA and reverse transcriptase polymerase chain reaction (RT-PCR), and results were compared. Diagnostic accuracy indices and Kappa analysis were calculated.
Results. The sensitivity, specificity, positive and negative predictive values (PPV and NPV) of NS1 against RT-PCR was 98.31, 100, 100, and 99.3% and strength of agreement was perfect.
Conclusion. Antigen-based and molecular tests are a better tool for early diagnosis of dengue. The combined LF-ICT kits are highly sensitive, specific, user-friendly, compact, frugal and thus recommended for use in dengue outbreaks, field conditions and as bed side diagnostic tests, for confirmatory dengue diagnosis. Further studies are required to assess their utility in prognosis, surveillance and establishment of guidelines for dengue outbreaks.
Disclosures. 
